Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences

Research output: Contribution to journalReview ArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase III trials. The development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed in this review.

Original languageEnglish
Pages (from-to)78-85
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume27
DOIs
Publication statusPublished - 1 Apr 2016

Cite this

@article{370426c59dfa4e41bfa5a05e36dacd4a,
title = "Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences",
abstract = "Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase III trials. The development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed in this review.",
author = "Jun Yang and Young, {Morag J.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.coph.2016.02.005",
language = "English",
volume = "27",
pages = "78--85",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier",

}

Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences. / Yang, Jun; Young, Morag J.

In: Current Opinion in Pharmacology, Vol. 27, 01.04.2016, p. 78-85.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences

AU - Yang, Jun

AU - Young, Morag J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase III trials. The development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed in this review.

AB - Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase III trials. The development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=84959331256&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2016.02.005

DO - 10.1016/j.coph.2016.02.005

M3 - Review Article

VL - 27

SP - 78

EP - 85

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -